会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 25. 发明申请
    • SYNTHETIC COMPOUNDS WHICH BIND TO H. PYLORI, AND USES THEREOF
    • 合成化合物,其与H.PYLORI的结合,及其用途
    • WO1995025113A1
    • 1995-09-21
    • PCT/US1995003273
    • 1995-03-15
    • SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    • SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHDANISHEFSKY, Samuel, J.RANDOLPH, John, T.
    • C07H05/02
    • C07H15/10A61K39/0011C07H3/06C07H15/18C07H17/02C07K16/3015C07K16/44
    • The present invention provides a compound having structure (I), wherein A is selected from the group consisting of (i) an amino acid bearing an omega -amino group or an omega -(C=O)- group, (ii) an amino acid residue of a peptide, which residue bears an omega -amino group or an omega -(C=O)- group, and (iii) an amino acid residue of a protein, which residue bears an omega -amino group or an omega -(C=O)- group; wherein R1 is H, OH, NH2 or NHR4, where R4 is SO2Ph, a linear or branched chain alkyl or acyl group, or an aryl group; wherein M is a saccharide wherein n is an integer from 0 to 18, and where n is greater than 1, each M is independently the same or different; wherein p is either 0 or 1; wherein R2, R3, R5 and R6 are independently the same or different and are H or OH, with the proviso that geminal R2 and R3 are not both OH, and geminal R5 and R6 are not both OH; wherein X and Y are independently the same or different and are H2 or O; and wherein k is an integer greater than or equal to 1, with the proviso that when A is an amino acid bearing an omega -amino group or an omega -(C=O)- group, k is equal to 1.
    • 本发明提供具有结构(I)的化合物,其中A选自(i)具有ω-氨基或ω-(C = O) - 基团的氨基酸,(ii)氨基 肽的酸残基,该残基具有ω-氨基或ω-(C = O) - 基团,和(iii)蛋白质的氨基酸残基,该残基具有ω-氨基或ω- (C = O) - 基团; 其中R 1是H,OH,NH 2或NHR 4,其中R 4是SO 2 Ph,直链或支链烷基或酰基或芳基; 其中M是糖,其中n是0至18的整数,并且其中n大于1,每个M独立地相同或不同; 其中p是0或1; 其中R 2,R 3,R 5和R 6独立地相同或不同,为H或OH,条件是偕R 2和R 3不同时为OH,偕R 5和R 6不同时为OH; 其中X和Y独立地相同或不同,为H 2或O; 并且其中k是大于或等于1的整数,条件是当A是具有ω-氨基或ω-(C = O) - 基团的氨基酸时,k等于1。
    • 29. 发明申请
    • CAMPTOTHECIN ANALOGUES AND METHODS OF PREPARATION THEREOF
    • CAMPTOTHECIN类似物及其制备方法
    • WO1994011376A1
    • 1994-05-26
    • PCT/US1993006918
    • 1993-07-23
    • SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    • SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHDANISHEFSKY, Samuel, J.BORNMANN, William, G.SHEN, WangCOBURN, Craig, A.
    • C07D491/14
    • C07D491/14C07H17/00
    • Substituted analogues of camptothecin possessing cytotoxic activity towards cancer cells, of general structure (I), wherein E is H, CO2R, CONH2, CONHR, CONR2, acyl, or CN; X is H, OH, or OR; R , R , R and R are independently the same or different and are H, or a linear or branched chain alkyl, alkylaryl, or hydroxyalkyl group, or an aryl group; R , R , R , R and R are independently the same or different and are H, or a linear or branched chain alkyl, alkylaryl, alkoxy, hydroxyalkyl, or aminoalkoxy group, or an aryl or aryloxy group, or a C-glycal, or CO2R, nitro, cyano, Cl, F, Br, I, SR , NR R , or OR ; R is H, or a linear or branched chain alkyl, alkylaryl, or hydroxyalkyl group, or an aryl group; R , R and R are independently the same or different and are H, or a linear or branched chain alkyl, alkylaryl, hydroxyalkyl, or acyl group, or an aryl group; R is glycosyl; n is 0 or 1; with the proviso that when R is ethyl, and n is 0, E, R , R and R are not all H. Intermediate compounds leading to the camptothecin analogues comprise substituted tricyclic compounds which consist of rings C, D and E fused together. Methods for preparing the analogues involve condensation of such intermediates with variably substituted protected alpha -aminobenzaldehydes.
    • 具有一般结构(I)的癌细胞具有细胞毒性活性的喜树碱的取代类似物,其中E是H,CO 2 R,CONH 2,CONHR,CONR 2,酰基或CN; X是H,OH或OR; R 1,R 2,R 3和R 4独立地相同或不同,为H,或直链或支链烷基,烷基芳基或羟基烷基或芳基; R 5,R 6,R 7,R 8和R 9独立地相同或不同,为H,或直链或支链烷基,烷基芳基,烷氧基,羟基烷基或氨基烷氧基 氰基,Cl,F,Br,I,SR 10,NR 11 R 12或OR 13中的至少一个或多个。 R是H或直链或支链烷基,烷基芳基或羟基烷基或芳基; R 10,R 11和R 12独立地相同或不同,为H,或直链或支链烷基,烷芳基,羟基烷基或酰基或芳基; R 13是糖基; n为0或1; 条件是当R 1是乙基且n是0时,E,R 2,R 3和R 4不是全部H.导致喜树碱类似物的中间体化合物包括取代的三环化合物,其中 由融合在一起的环C,D和E组成。 制备类似物的方法涉及这种中间体与可变取代的被保护的α-氨基苯甲醛的缩合。